Nanoparticle-based strategy for personalized B-cell lymphoma therapy

• Published in: International journal of nanomedicine 2016-01, Vol.11, p.6089-6101
• Main Authors: Martucci, Nicola M, Migliaccio, Nunzia, Ruggiero, Immacolata, Albano, Francesco, Calì, Gaetano, Romano, Simona, Terracciano, Monica, Rea, Ilaria, Arcari, Paolo, Lamberti, Annalisa
• Format: Article
• Language: English
• Subjects: active targeting; Animals; Antigens, Neoplasm - metabolism; Apoptosis; B cells; Bcl2; Cancer; Cancer therapies; Care and treatment; Cell Line, Tumor; Chemotherapy; diatomite; Drug delivery systems; Drugs; Efficiency; Flow Cytometry; Gene Silencing; Genes, bcl-2 - genetics; Ligands; Lymphoma; Lymphoma, B-Cell - drug therapy; Lymphoma, B-Cell - genetics; Mice, Inbred BALB C; Microscopy, Confocal; Molecular Targeted Therapy; Morphology; Nanoparticles; Nanoparticles - administration & dosage; Nanoparticles - chemistry; Non-Hodgkin's lymphomas; Original Research; Peptides; personalized therapy; Precision Medicine - methods; Real-Time Polymerase Chain Reaction; RNA; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - genetics; small interfering RNA; Vehicles
• ISSN: 1178-2013; 1176-9114; 1178-2013
• DOI: 10.2147/IJN.S118661

B-cell lymphoma is associated with incomplete response to treatment, and the development of effective strategies targeting this disease remains challenging. A new personalized B-cell lymphoma therapy, based on a site-specific receptor-mediated drug delivery system, was developed in this study. Specifically, natural silica-based nanoparticles (diatomite) were modified to actively target the antiapoptotic factor B-cell lymphoma/leukemia 2 (Bcl2) with small interfering RNA (siRNA). An idiotype-specific peptide (Id-peptide) specifically recognized by the hypervariable region of surface immunoglobulin B-cell receptor was exploited as a homing device to ensure specific targeting of lymphoma cells. Specific nanoparticle uptake, driven by the Id-peptide, was evaluated by flow cytometry and confocal microscopy and was increased by approximately threefold in target cells compared with nonspecific myeloma cells and when a random control peptide was used instead of Id-peptide. The specific internalization efficiency was increased by fourfold when siRNA was also added to the modified nanoparticles. The modified diatomite particles were not cytotoxic and their effectiveness in downregulation of gene expression was explored using siRNA targeting Bcl2 and evaluated by quantitative real-time polymerase chain reaction and Western blot analyses. The resulting gene silencing observed is of significant biological importance and opens new possibilities for the personalized treatment of lymphomas.